Valuation: AstraZeneca Pharma India Limited

Market Cap 16TCr 167.65Cr 150.15Cr 138.11Cr 125.14Cr 233.92Cr 238.3Cr 1.65TCr 661.16Cr 8.37TCr 629.17Cr 615.79Cr 26TCr P/E 2025
186x
P/E 2026 103x
Enterprise Value 16TCr 164.1Cr 146.97Cr 135.19Cr 122.49Cr 228.96Cr 233.25Cr 1.61TCr 647.16Cr 8.2TCr 615.85Cr 602.75Cr 26TCr EV / Sales 2025
12.2x
EV / Sales 2026 8.38x
Free-Float
19.52%
Yield 2025
0.37%
Yield 2026 0.46%
1 day+1.10%
1 week+6.33%
Current month+2.89%
1 month+2.89%
3 months-21.29%
6 months-22.51%
Current year-29.33%
1 week 5,890.3
Extreme 5890.3
6,385
1 month 5,660
Extreme 5660
6,385
Current year 5,660
Extreme 5660
9,219.25
1 year 5,660
Extreme 5660
9,850
3 years 4,050.15
Extreme 4050.15
10,653.05
5 years 2,437.75
Extreme 2437.75
10,653.05
10 years 882.55
Extreme 882.55
10,653.05
Manager TitleAgeSince
Chief Executive Officer - 01/07/2025
Chief Tech/Sci/R&D Officer - 03/03/2025
Compliance Officer - 23/02/2026
Director TitleAgeSince
Director/Board Member 67 02/12/2016
Chairman 52 30/09/2024
Director/Board Member - 09/11/2023
Change 5-day change 1-year change 3-year change Capi.($)
+1.10%+6.33%-32.71%+34.50% 167.65Cr
+3.19%+11.31%+67.86%+150.58% 1,26300Cr
-0.73%+3.56%+44.51%+85.81% 66TCr
+1.41%+3.24%+29.22%+107.83% 52TCr
+0.42%+3.20%+54.15%+67.18% 39TCr
+2.18%+2.93%+73.30%+45.62% 37TCr
+1.12%+4.52%+35.30%+58.08% 31TCr
+6.96%+8.86%+11.27%+36.62% 29TCr
+1.15%+6.09%+59.59%+77.06% 25TCr
+3.06%+9.38%+44.11%+119.47% 21TCr
Average +1.67%+5.94%+38.66%+78.27% 42.64TCr
Weighted average by Cap. +1.19%+6.60%+50.85%+98.29%

Financials

2025 2026
Net sales 1.72TCr 18Cr 16Cr 15Cr 13Cr 25Cr 26Cr 177.58Cr 71Cr 902.82Cr 68Cr 66Cr 2.85TCr 2.28TCr 24Cr 21Cr 20Cr 18Cr 33Cr 34Cr 235.44Cr 95Cr 1.2TCr 90Cr 88Cr 3.77TCr
Net income 115.74Cr 1.22Cr 1.09Cr 1Cr 90.99L 1.7Cr 1.73Cr 12Cr 4.81Cr 61Cr 4.57Cr 4.48Cr 192Cr 187.52Cr 1.97Cr 1.77Cr 1.63Cr 1.47Cr 2.76Cr 2.81Cr 19Cr 7.79Cr 99Cr 7.41Cr 7.25Cr 311.08Cr
Net Debt -500.41Cr -5.27Cr -4.72Cr -4.34Cr -3.93Cr -7.35Cr -7.49Cr -52Cr -21Cr -263.23Cr -20Cr -19Cr -830.13Cr -337.06Cr -3.55Cr -3.18Cr -2.92Cr -2.65Cr -4.95Cr -5.05Cr -35Cr -14Cr -177.3Cr -13Cr -13Cr -559.15Cr
Projected Income Statement - Annual - AstraZeneca Pharma India Limited
Logo AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is an India-based biopharmaceutical company. Its therapeutic areas include cardiovascular, renal and metabolism; chronic and respiratory diseases. The Company operates through Healthcare segment. The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and also provides clinical trial services to an overseas group company. Its therapeutic offerings in CVRM business include heart failure, and chronic kidney disease indications for Forxiga (Dapagliflozin). Its approvals in oncology business include the use of Imfinzi (Durvalumab) in Biliary Tract Carcinoma, and use of Lynparza (Olaparib) in early breast cancer. The Company has a portfolio of oral antidiabetic drugs with presence in two drug classes: SGLT2 inhibitors and DPP4 inhibitors. The Company’s DPP4 offering comprises of the brands of Onglyza (Saxagliptin) and Kombiglzye (Saxagliptin/Metformin).
Employees
760
Date Price Change Volume
30/26/30 ₹6,367.35 +1.10% 119
29/26/29 ₹6,298.05 +1.02% 410
28/26/28 ₹6,234.70 +2.66% 1,034
27/26/27 ₹6,073.10 -0.03% 120
26/26/26 ₹6,074.75 +1.45% 266
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ASTRAZEN Stock